Medicare’s own advisors say hospital buyouts of doctor offices are adding extra “facility fees” to routine visits—and those quiet charges roll straight onto patient bills.
Story Snapshot
- Medicare Payment Advisory Commission (MedPAC) links physician buyouts to higher payments via facility fees.
- Earlier MedPAC work ties hospital-physician consolidation to higher prices for both Medicare and commercial payers.
- Congressional Budget Office (CBO) finds insurer–pharmacy benefit manager tie-ups can lower drug prices, but other vertical deals may raise costs.
- Experts warn payment gaps steer care to higher-priced hospital settings without clear gains for patients.
What MedPAC says is driving higher bills
Medicare’s advisory panel reports that when hospitals buy physician practices, billing often shifts to a hospital outpatient model. That shift lets systems add a “facility fee” on top of the doctor charge. The result is higher Medicare spending and higher patient cost sharing for the same visit in the same office, now re-flagged as hospital-owned. MedPAC has long warned that such site-based payment differentials reward consolidation and nudge care into higher-priced settings with no clear benefit to the patient.
MedPAC’s earlier work concluded that hospital-physician consolidation increases prices paid for physician services across both Medicare and commercial markets. That means seniors, employers, and workers often pay more after mergers. The mechanism is simple. Combined systems gain leverage to command higher prices, and payment rules allow higher rates in hospital outpatient departments. Those two forces pull in the same direction. Patients do not pick this; ownership and billing rules do. That is a policy choice, not a medical one.
How site-based payments and steering raise costs
Payment rules pay more for the same service in a hospital outpatient department than in an independent office. When a health system buys a clinic, the sign may not change, but the bill does. Added facility fees and higher outpatient rates ripple through common services like checkups, imaging, and minor procedures. MedPAC’s March 2026 chapter explains how systems “exploit” these differentials after acquisitions, which lifts Medicare spending and the share that beneficiaries owe out of pocket.
Steering does not stop at office visits. Once a system controls clinics, hospitals, and pharmacies, it can keep referrals inside its network. A witness statement to Congress cited the Federal Trade Commission’s work arguing that pharmacy benefit manager ties can channel specialty drugs to affiliated pharmacies at higher reimbursements, raising questions about who benefits from the spread between prices and costs. Patients often have no say when software and contracts guide where they go. The bill reflects those upstream decisions, not patient choice.
Where vertical integration may help—and where it likely hurts
Not all integration is the same. The Congressional Budget Office reports that when insurers own pharmacy benefit managers, aligned incentives can lower the prices paid for drugs by those plans’ enrollees, cutting patient spending at the pharmacy counter. That is a real gain for some families who fill costly prescriptions. But CBO also flags that other forms of consolidation, such as hospitals buying off-site clinics, generally increase prices paid by Medicare and commercial insurers by boosting bargaining power and shifting billing to higher-rate settings.
This split picture explains why many Americans across the aisle feel squeezed. People see premiums, deductibles, and coinsurance rise while networks shrink and surprise facility fees appear. They do not feel better “care coordination.” They feel higher bills. MedPAC’s findings match that lived reality on the medical side. CBO’s work shows drug savings can exist inside certain corporate stacks, but those savings do not erase broader price hikes from physician-hospital consolidation.
What reforms are on the table now
Policy analysts point to “site-neutral” payment reforms that would pay the same rate for the same service, no matter who owns the building. MedPAC has urged Congress to close gaps that reward billing shifts instead of better care. Narrowing those gaps could stop deals that exist mainly to reclassify services. Lawmakers are also weighing guardrails on pharmacy benefit manager practices to ensure any savings from integration flow to patients, not just to affiliated middlemen and owners.
Real change will test both parties. Republicans push lower spending and market discipline. Democrats push fairness and consumer protection. Site-neutral payment is one place those goals align. It targets waste without cutting necessary care. Transparency on referral steering and pharmacy spreads is another. Both steps confront a system that too often pays more for the label on the door than for the care inside, and patients end up footing the bill.
What this means for your wallet
Ask before you book: Is this visit billed as hospital outpatient, and will there be a facility fee? Request price estimates for imaging and labs in independent settings. Check whether your plan passes drug rebates or negotiated savings through to you at the counter. These small steps cannot fix policy, but they can help you avoid the traps that MedPAC and CBO describe. The bigger fix is on Congress: pay the same price for the same care, stop steering by ownership, and make savings reach patients.
Sources:
medpac.gov, warren.senate.gov, congress.gov, sciencedirect.com
